Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

Takeda’s oveporexton among key value-driving biopharma catalysts in Q3 2026, reveals GlobalData

Regulatory catalysts are set to shape biopharma sentiment in Q3 2026, with a selective pipeline of approval decisions and clinical milestones highlighting where innovation is most likely to create value. Foremost among them is Takeda Pharmaceutical’s oveporexton, whose anticipated FDA decision could validate a disease-modifying approach in narcolepsy type 1 (NT1), while pivotal readouts across […]
Read more

Biotech funding recovery favors late-stage, lower-risk assets, reveals GlobalData

The biopharmaceutical industry has seen a recovery in funding through 2026, following a prolonged downturn that limited access to capital across the sector. This recovery includes investment increasingly concentrated in later-stage, lower risk assets rather than early-stage innovation, according to GlobalData, a leading intelligence and productivity platform. According to GlobalData’s State of the Biopharmaceutical Industry […]
Read more

GLP1-RAs emerge as biopharma’s most influential platform drug class, reveals GlobalData

GLP-1 receptor agonists (GLP-1RAs) have contributed significantly to the therapeutic landscape, evolving from a primarily diabetes treatment into leading weight-loss assets with multi-indication capabilities across global pharmaceutical markets. What changed is not just awareness but the convergence of unmet need, a step change in efficacy, and expanding proof of value, turning GLP-1RAs from a diabetes […]
Read more

Biopharma confidence reaches four-year high as dealmaking and innovation gather pace, finds GlobalData

Confidence in the biopharmaceutical industry has climbed to its highest point since 2022, signaling a sector that is regaining momentum despite persistent regulatory and market pressures. The rebound reflects the impact of strategic restructuring, disciplined capital allocation, and renewed investment in innovation. As dealmaking accelerates and funding sentiment improves, the industry appears increasingly positioned to […]
Read more

AI integration in pharmaceutical processes remains focused on high-impact functions, says GlobalData

Artificial Intelligence (AI) has shifted from an experimental technology to an industry-wide operational tool across the pharmaceutical value chain. Companies are prioritizing AI deployment in high-impact areas such as drug discovery, clinical trials, and medical writing, where returns are most tangible. As confidence in AI’s commercial value strengthens, the technology is reshaping R&D economics, accelerating […]
Read more

US drug approvals surpass 10-year average in 2025, reveals GlobalData

The US FDA approved 131 drugs last year through its New Drug Application (NDA), Biologics License Application (BLA), and biosimilar pathways, leading to a steady 4.8% year-on-year increase in approvals. After an uneven decade in which new drug approvals fluctuated widely, the number approved by US regulators in 2025 exceeded the 10-year average, according to […]
Read more

Immunology and neurology drug development enters transformational era, says GlobalData

The landscape of both immunology and neurology therapeutics is currently undergoing a paradigm shift. Immunology therapeutics are moving beyond conventional tumor necrosis factor (TNF)-alpha inhibitors, Janus kinase (JAK) inhibitors, and interleukin (IL)-6 antagonists toward precision-targeted modalities that address fundamental immune dysregulation. Meanwhile, in neurology, precision biologics, gene therapies, and psychedelic-assisted modalities are converging toward a […]
Read more

China poised to launch first stand-alone opioid-induced constipation treatment, says GlobalData

China is confronting a rising oncology burden alongside the challenge of opioid-induced constipation (OIC), a common and debilitating side effect of opioid-based pain treatment. The National Medical Products Administration (NMPA) recently approved Shionogi’s Symproic (naldemedine), the first peripherally acting μ-opioid receptor antagonist (PAMORA) for OIC, marking an important step forward in supportive care and pain […]
Read more

Male infertility market growth to be driven by increased awareness and population growth, says GlobalData

The male infertility pharmaceutical market across the seven major markets (7MM: US, 5EU, and Japan) is projected to grow at a compound annual growth rate (CAGR) of 2.9% between 2025 and 2035, driven primarily by rising awareness of male reproductive health and continued population growth, according to GlobalData, a leading intelligence and productivity platform. GlobalData’s […]
Read more

DPP1 inhibitors reinforced with long-term phase II pooled data from verducatib, says GlobalData

Positive pooled long-term data from Phase II interim results for Boehringer Ingelheim’s verducatib, presented at the recent ATS 2026 International Conference, demonstrated the pipeline asset’s potential to reduce the risk of pulmonary exacerbations (PEx) in non-cystic fibrosis bronchiectasis (NCFB) patients. The results provide validation of the dipeptidyl peptidase 1 (DPP1)/cathepsin C inhibition in NCFB and […]
Read more

Long-term data continue to bolster Trikafta’s dominant position in the cystic fibrosis market, says GlobalData

Positive long-term data for Trikafta, that was presented at the ATS 2026 International Conference, reinforces the therapy’s efficacy in adult cystic fibrosis (CF) patients with at least one F508del allele. The findings highlighted improvements in clinical and biochemical parameters, strengthening Trikafta’s leadership in the CF market and supporting informed patient monitoring and broader post-authorization market […]
Read more

FDA accelerated approval of Hepcludex to address serious unmet need in US HDV market, says GlobalData

The US Food and Drug Administration (FDA) has recently granted accelerated approval to Gilead Sciences’ antiviral, Hepcludex (bulevirtide-gmod), for the treatment of adults with chronic hepatitis delta virus (HDV) infection without cirrhosis or with compensated cirrhosis. Hepcludex is now the first and only approved treatment for HDV patients in the US, marking a significant milestone […]
Read more

ATS 2026: TETON-PPF study reinforces inhaled therapies potential in progressive pulmonary fibrosis, says GlobalData

Emerging Phase III evidence for inhaled treprostinil in progressive pulmonary fibrosis (PPF) is reinforcing industry expectations that combination therapy will shape the next phase of fibrotic lung disease treatment. TETON-PPF trial data presented at the 2026 American Thoracic Society (ATS) International Conference highlights the potential for inhaled therapies to complement existing antifibrotics, while intensifying competitive […]
Read more

ATS 2026: Jascayd reinforces combination therapy shift in US pulmonary fibrosis treatment, says GlobalData

New US subgroup data for Jascayd in idiopathic and progressive pulmonary fibrosis (IPF/PPF) is reinforcing the industry shift toward combination antifibrotic therapy in fibrotic lung disease management. Findings suggest the therapy can deliver meaningful clinical benefit alongside existing standard-of-care treatments, strengthening its commercial positioning as competitive intensity accelerates across the evolving pulmonary fibrosis treatment landscape, […]
Read more

Surveillance and prevention critical for Ebola control amid lack of effective prophylactics or therapeutics, says GlobalData

Following WHO reports of 53 confirmed cases, 600 suspected cases, and 139 suspected deaths from the ongoing Ebola outbreak in the Democratic Republic of the Congo (DRC) and Uganda; Anaelle Tannen, Senior Infectious Disease Analyst at GlobalData, a leading intelligence and productivity platform, offers her view: “On May 17, 2026, the WHO declared the Ebola […]
Read more

PABPC4 identification as key regulator of mitochondrial dysfunction signals potential for precision medicine in COPD, says GlobalData

A novel genetic mechanism underlying chronic obstructive pulmonary disease (COPD) is gaining attention, with new data identifying PABPC4 as a key regulator of mitochondrial function and emphysema pathogenesis. Early findings demonstrating the correction of a causal splicing defect using a first-in-class therapeutic approach signal potential for precision medicine in COPD, says GlobalData, a leading intelligence […]
Read more
1 2 3 4 5 … 110